Wealthstreet Investment Advisors LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 1.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,729 shares of the company’s stock after buying an additional 1,327 shares during the period. Johnson & Johnson accounts for approximately 1.6% of Wealthstreet Investment Advisors LLC’s investment portfolio, making the stock its 15th largest position. Wealthstreet Investment Advisors LLC’s holdings in Johnson & Johnson were worth $12,358,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of JNJ. Evolution Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $40,000. Horan Securities Inc. raised its holdings in shares of Johnson & Johnson by 122.3% in the 4th quarter. Horan Securities Inc. now owns 438 shares of the company’s stock valued at $56,000 after purchasing an additional 241 shares in the last quarter. FNY Investment Advisers LLC raised its holdings in shares of Johnson & Johnson by 594.4% in the 4th quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock valued at $64,000 after purchasing an additional 428 shares in the last quarter. Thor Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 1st quarter valued at $69,000. Finally, CKW Financial Group raised its holdings in shares of Johnson & Johnson by 18.8% in the 4th quarter. CKW Financial Group now owns 810 shares of the company’s stock valued at $105,000 after purchasing an additional 128 shares in the last quarter. 66.78% of the stock is owned by institutional investors and hedge funds.
In related news, Director Marillyn A. Hewson purchased 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, for a total transaction of $419,040.00. Following the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $419,040. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.23% of the stock is owned by company insiders.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.63%. The firm had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. During the same period last year, the business earned $2.10 EPS. Johnson & Johnson’s revenue for the quarter was down 1.3% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be paid a dividend of $0.95 per share. The ex-dividend date is Monday, August 26th. This represents a $3.80 annualized dividend and a yield of 2.90%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
A number of equities research analysts have recently weighed in on the stock. Goldman Sachs Group assumed coverage on shares of Johnson & Johnson in a report on Tuesday, May 28th. They issued a “buy” rating on the stock. Raymond James reduced their price objective on shares of Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a report on Wednesday, July 17th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Bank of America restated a “hold” rating and issued a $150.00 price objective on shares of Johnson & Johnson in a report on Tuesday, July 16th. Finally, Barclays initiated coverage on shares of Johnson & Johnson in a report on Friday, June 21st. They issued a “hold” rating and a $140.00 price objective on the stock. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $148.56.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.